Skip to main content
Premium Trial:

Request an Annual Quote

Vala Sciences Enters Market with Cell Image-Based Reagents, Analysis Software Tools

NEW YORK, Feb. 16 (GenomeWeb News) - Vala Sciences will now begin to sell cell image-based reagents and analysis software tools for academic, pharmaceutical, and biotech scientists, the company said today.

 

The LaJolla, Calif.-based start-up, less than a year old, also announced that it is starting off with $3.5 million in funding from the National Institutes of Health, the California Technology Investment Partnership Program, and private individual investors.

 

Vala's core team, headed by CEO Jeffrey Price, said that its automated technology would save researchers weeks of time when analyzing images attained by fluorescence-based microscopy. Price formerly developed software for microscopy analysis for Q3DM.

 

According to Vala, collaborations have already been initiated with the Chemical Genomics Research Consortium of the Gulf Coast Consortia, The Burnham Institute, Regenemed, and the University of Florida for a variety of projects.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.